Literature DB >> 8081360

Asymptomatic homozygous hypobetalipoproteinemia associated with apolipoprotein B45.2.

S G Young1, B Bihain, L M Flynn, D A Sanan, M Ayrault-Jarrier, B Jacotot.   

Abstract

Familial hypobetalipoproteinemia is caused by apolipoprotein (apo) B gene mutations and is frequently associated with a truncated apo-B protein in the plasma. Homozygosity for mutations yielding a truncated apo-B is extremely rare; fewer than five true homozygotes have been described in the world's literature. These patients typically have normal levels of triglycerides and virtually absent low density lipoprotein (LDL) cholesterol. The clinical status of these patients is variable, ranging from asymptomatic in two homozygotes who synthesized a truncated apo-B (apo-B87) to severe neurological disease resulting from vitamin E deficiency in a homozygote who synthesized a shorter apo-B (apo-B50). In this report, we describe a 48-year-old female homozygous for a nonsense mutation resulting in an even shorter apo-B, apo-B45.2. Although this individual had virtually no LDL cholesterol, she was asymptomatic and had normal plasma levels of vitamin E. This case demonstrates that homozygosity for an apo-B mutation associated with a relatively short apo-B truncation can be completely asymptomatic.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8081360     DOI: 10.1093/hmg/3.5.741

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  2 in total

1.  Unusual presentation of three siblings with familial heterozygous hypobetalipoproteinaemia.

Authors:  V Kairamkonda; M Dalzell
Journal:  Eur J Pediatr       Date:  2003-01-11       Impact factor: 3.183

Review 2.  Mechanisms and genetic determinants regulating sterol absorption, circulating LDL levels, and sterol elimination: implications for classification and disease risk.

Authors:  Sebastiano Calandra; Patrizia Tarugi; Helen E Speedy; Andrew F Dean; Stefano Bertolini; Carol C Shoulders
Journal:  J Lipid Res       Date:  2011-08-23       Impact factor: 5.922

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.